An interventional study of Nordlys SWT IPL and Meibomian Gland Expression (MGX) in Meibomian Gland Dysfunction and Dry Eye Disease, sponsored by Candela Corporation. Active, not recruiting at 3 sites in 2 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Candela Corporation · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Meibomian Gland Dysfunction with a site in United States — 7 open to participants now, 11 under way, none of them phase 3. Meibomian Gland Dysfunction · United States.
Among the 64 studies in Meibomian Gland Dysfunction with a site in United States, this one is the 14th largest by planned enrollment of the 62 interventional ones that give a count, is one of 6 that started in 2023, is one of 43 with no phase, reaches primary completion later than 10 of the 10 other live ones, and was the 52nd registered.
173 studies on the registry are indexed under Meibomian Gland Dysfunction; 23 are open to participants now.
Browse Meibomian Gland Dysfunction studies →7 of the 64 studies in Meibomian Gland Dysfunction with a site in United States are open now. Recruiting first, the newest first:
Cleveland Eye Clinic · Sites in United States
Ages 50–75
University of Alabama at Birmingham · Sites in United States
Ages 18+
University of California, Berkeley · Sites in United States
Ages 18+
University of Houston · Sites in United States
Ages 18+
Illinois College of Optometry · Sites in United States
Ages 6–18 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Meibomian Gland Dysfunction studies recruiting now, 10 (77%) set no upper age limit and 1 (8%) stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 4 7
First in 2008; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 50 across 139 interventional studies indexed under Meibomian Gland Dysfunction.
Median enrollment 44 across the 62 interventional studies, 33 across the 2 observational. Of the 44 that completed or were terminated, 30 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 64 have an industry lead sponsor. The 10 most frequent:
This study is registered under Candela Corporation, one of the names counted as Candela. Under that name alone:
Candela Corporation is the lead sponsor of 19 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.
Candela has 1 study filed under Meibomian Gland Dysfunction — fewer than ten, so there is no comparison to draw.
7 of the studies in Meibomian Gland Dysfunction with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07928986Cleveland Eye ClinicA Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery | 2026-12 |
| NCT07229001Illinois College of OptometryTreating Meibomian Gland Disease in a Pediatric Population | 2026-12-30 |
| NCT07939360Essilor InternationalEvaluation of the Espansione Equinox System Safety & Effectiveness for the Treatment of Meibomian Gland Dysfunction. | 2026-12-31 |
| NCT07606625University of California, BerkeleyOcular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment | 2026-12-31 |
| NCT07224529University of Alabama at BirminghamEfficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction | 2027-02-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 64 studies in Meibomian Gland Dysfunction with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Clinical Study Evaluating Nordlys™ System with Selective Waveband Technology (SWT)® Intense Pulsed Light (IPL) Applicators for Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD).
Subjects will be randomized 1:1 to an experimental study group and a sham comparator (control) group.
Subjects in the experimental group will receive four (4) IPL treatments and meibomian gland expression (MGX) at 2-week intervals. IPL pulses will be administered on the skin of the malar region and below the lower eyelids. Following IPL therapy, subjects will undergo MGX of both eyelids in both eyes. Subjects in the control group will receive the same treatment (IPL followed by MGX), except that the IPL administration will be performed with the device off (sham treatment). Follow-up visits will occur at 1 month and 3 months after the final treatment session. At the follow-up, the changes in the outcome measures will be evaluated and compared between the two groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive up to four study Nordlys SWT IPL treatments and MGX
Device: Nordlys SWT IPL · Procedure: Meibomian Gland Expression (MGX)
Subjects will receive up to four sham study Nordlys SWT IPL treatments (device turned off) and MGX
Procedure: Meibomian Gland Expression (MGX) · Device: Sham Nordlys SWT IPL
Nordlys™ System with Selective Waveband Technology (SWT)® IPL Applicators
Meibomian glands are squeezed (by applying force on the inner and outer surfaces of the eyelid with a specially designed forceps, Q-tips, or fingers) in order to unclog obstructed glands and evacuate their content (the meibum), which in MGD is often viscous and thus causing obstruction
Sham treatment with Nordlys™ System with Selective Waveband Technology (SWT)® IPL Applicators device turned off
Improvement of Tear Breakup Time (TBUT) from baseline to 4-week follow-up
The difference in the change of TBUT from Baseline to Follow-Up, between eyes in the study group and eyes in the control group. TBUT is measured in seconds. Improvement is defined as a positive change of TBUT from Baseline to Follow Up. Measurement of TBUT will be implemented using fluorescein ophthalmic strips. Three successive readings will be taken and averaged to a single value.
Time frame: Baseline, 4-Week Follow Up (Week 10)
Difference in change of self-assessed symptoms with the Ocular Surface Disease Index (OSDI) questionnaire, from baseline to follow-up.
The difference in the change of OSDI from baseline to FU, between subjects in the study group and subjects in the control group. The minimal number is 0 and the maximal number is 100. Higher scores mean worse outcome. A score of 0-12 is considered normal. A score of 13-22 is consistent with mild dry eye. A score of 23 to 32 is consistent with moderate dry eye. A score from 33 to 100 is consistent with severe dry eye. The improvement of OSDI is defined as a negative change of OSDI from BL to FU.
Time frame: Baseline, 1 Month Follow Up at Week 10, and 3 Month Follow Up at Week 18
The difference in change of self-assessed symptoms of eye dryness via Eye Dryness Score (EDS) via visual analog scale (VAS), from baseline to follow-up
A qualitative test to visualize the production of sweat to the affected body area and assist in determining the area requiring treatment. Values will be collected separately for each eye. Correlation between eyes was removed by statistical methods. Scores were 0 (minimum) to 100 (maximum). Higher scores = worse outcome. The improvement of EDS is defined as a negative change of EDS from baseline to follow-up.
Time frame: Baseline, 1 Month Follow Up at Week 10, and 3 Month Follow Up at Week 18
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Sep 2027, 48 months after the start.
Of 23 industry-sponsored interventional studies with no phase under Meibomian Gland Dysfunction, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 15. This study's planned 48 months is above that.
Counting every sponsor, half of 75 studies reached it within 11 months; a quarter within 5 and three quarters within 19.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Sep 2025 → Sep 2027 and completion Sep 2025 → Sep 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.